BioTuesdays

Category - Markets

Collegium Pharma
Markets

HCW starts Collegium at buy

H.C. Wainwright initiated coverage of Collegium Pharmaceuticals (NASDAQ:COLL) with a “buy” rating and $21 price target. The stock closed at $10.21 on Sept. 8. Collegium is a leading player in the abuse-deterrent...

September 11, 2017
NewLink Genetics
Markets

Stifel ups NewLink price target to $29

Stifel raised its price target for NewLink Genetics (NASDAQ:NLNK) to $29 from $14 after the company on the weekend updated Phase 2 data in patients with advanced melanoma. The stock closed at $17.67 on Sept. 8. In a...

September 11, 2017
NeoGenomics
Markets

BTIG cuts NeoGenomics to neutral

BTIG downgraded NeoGenomics (NASDAQ:NEO) to “neutral” from “buy,” citing hurricanes that have hit Texas and Florida and noting that the shares are near its $11 price target, almost reaching an all-time high. The stock...

September 11, 2017
Flex Pharma
Markets

Roth restarts Flex Pharma at buy

Roth Capital Partners reinitiated coverage of Flex Pharma (NASAQ:FLKS) with a “buy” rating and $14 price target. The stock closed at $3.37 on Sept. 6. Flex is developing FLX-787, an innovative anti-cramp drug in...

September 7, 2017
Verastem
Markets

HCW ups Verastem price target to $10

H.C. Wainwright raised its price target for Verastem (NASDAQ:VSTM) to $10 from $6.50 after the company reported positive top-line results from a Phase DUO study of duvelisib for the treatment of relapsed/refractory...

September 7, 2017
theralase logo
Markets

Echelon starts Theralase at speculative buy

Echelon Wealth Partners initiated coverage of Theralase Technologies (TSXV:TLT) with a “speculative buy” rating and one-year price target of 90 cents. The stock closed at 47 cents on Sept. 1. Analyst Doug Loe writes...

September 5, 2017
Clementia
Markets

BTIG starts Clementia at buy

BTIG initiated coverage of Clementia Pharmaceuticals (NASDAQ:CMTA) with a “buy” rating and 12-month price target of $32, saying the company’s lead molecule, palovarotene, presents a plethora of promising possibilities...

August 31, 2017
Gemphire Logo
Markets

HCW starts Gemphire at buy

H.C. Wainwright launched coverage of Gemphire Therapeutics (NASDAQ:GEMP) with a “buy” rating and a price target of $21, saying it views the sell off in the shares following results of the ROYAL-1 clinical trial as...

August 31, 2017
KalVista Pharmaceuticals Logo
Markets

BTIG starts KalVista at buy

BTIG launched coverage of KalVista Pharmaceuticals (NASDAQ:KALV) with a “buy” rating and $18 price target. The stock closed at $6.59 on August 30. KalVista is focused on developing a portfolio of oral plasma kallikrein...

August 31, 2017
Innate Pharma Logo
Markets

HCW starts Innate Pharma at buy

H.C. Wainwright initiated coverage of French-based Innate Pharma (PSE:IPH) with a “buy” rating and price target of €16.50. The stock closed at €10.70 on August 29. Analyst Swayampakula Ramakanth writes that Innate is...

August 30, 2017